Pharmafile Logo

Ageing in China: The Implications for Healthcare

March 27, 2015 | China 

Published in eye for pharma 12 December by Marc Yates

China’s population has aged much faster than other populations, and this rapid ageing poses challenges to healthcare, among which the most common are a surging healthcare expenditure and a rising difficulty in managing the ‘iron triangle’.

Rapid demographic shifts

China’s population has aged much faster than other populations, and the proportion of elderly among the total population is set to remain very high for years to come. The average time taken by developed countries for the percentage of the population above 65 years old to increase from 7% to 17% was 60 years, but China is expected to take only 30 years to reach the same level.  By 2050, the proportion of the population over 65 in China is projected to reach 34%, which is comparable with Denmark, and much higher than the US (26%).

Increased longevity and lower fertility rate are typically the two main factors that contribute to an ageing population. In the case of China, the strict family planning policy (one-child policy) implemented in 1980 has played a key role in the country’s rapid shift in population structure. As each family is only allowed to have one child, China’s fertility rate has dropped sharply in the wake of the policy, resulting in a declining percentage of young population. This is a key factor that we need to bear in mind when looking at China’s unique healthcare challenges.

The Challenges

Rapid ageing poses challenges to healthcare, among which the most common are a surging healthcare expenditure, and a rising difficulty in managing the ‘iron triangle’ – access, cost and quality, the three core aspects of healthcare that need to be balanced by any healthcare regulator.

So what are the unique constraints that China faces because of ageing?

Financial constraints – ‘Getting old before getting rich’

China is the only developing country with ageing at a level comparable to many developed countries. This means the amount of public resources for elderly care are limited. In the past ten years, China’s government has channelled significant investment into establishing a public health insurance that covers 95% of the population. However, such wide coverage could only be achieved by providing a very low benefit level to each citizen. The financial stability of this public investment is also questionable, as China’s healthcare expenditure is expected to increase by five times from 2000 to 2020, as people above 65 years of age typically spend three to five times more on healthcare than those below 65. As the demand for public funding increases, the trade-off between access and quality will intensify. In addition, China’s public health insurance is structured such that the healthcare of the elderly population is funded by paid contributions from the employed workforce. Since China also faces a declining labour force after three decades of the one-child policy, the current system is likely to meet great challenges as incoming funding from salaried contributions falls short of outgoing healthcare expenditure.

On a micro level, family support for elderly healthcare also faces constraints as a result of rapid ageing. Traditionally, the majority of elderly care in China has been provided by families. However, the long-term impact of the one-child policy has been not only to alter the population structure, but also to change the family structure. There are an increasing number of ‘4-2-1’ families, which stands for two adults supporting four elderly parents and their own child. This structure considerably hampers many families’ ability to provide elderly care, which in turn creates a new need for social elderly care, such as care centers. This is even more critical in rural areas, which account for two thirds of the ageing population and have significantly lower family income levels than urban areas. Moreover, China’s urbanization and industrialization has resulted in thousands of millions of the rural population migrating to cities for work, leaving the elderly behind in villages where healthcare access is limited.

Healthcare service constraints – ‘Demand outstripping supply’

A significant proportion of China’s elderly suffer from health problems. According to a recent survey, there are 62 million elderly experiencing body pain and 100 million having hypertension. Not only are the Chinese elderly experiencing a rising chronic disease burden, cognition decline and depression are also becoming increasingly prevalent among the elderly. An ageing population with suboptimal health is inevitably going to put significant pressure on its healthcare system, therefore we expect China to encounter a critical shortage of medical services supplied for the elderly, including lack of community care centers, palliative care and long-term care facilities. China is also set to experience a shortage of nurses, physiotherapists, and social workers as the burden of elderly care is being transmitted from family to society.

Implications for the healthcare industry

The Chinese government has started to implement major reforms in pharmaceutical policy to control healthcare expenses since the turn of the century, such as the Essential Drug List, a preferred list of drugs for public hospitals at an affordable price. In response to the increasing burden on the state and families to pay for healthcare due to ageing, we expect the government to devise additional measures to further curb healthcare costs. A hint of this trend is suggested by the ongoing campaign to reduce unnecessary and profit-driven prescriptions, as well as the recent anti-corruption investigations against multinational pharmaceutical companies.

For years, patients have complained about hospitals in China being overcrowded. This is due to the shortage of medical services supplied, as well as the lack of a gate-keeping system for primary care. China is planning to build a primary healthcare system that aims to increase access and relieve the burden of general hospitals. In the context of ageing, primary care such as community clinics is likely to be prioritized by the government given that it could provide more efficient healthcare at a lower cost, and would be a more convenient route for the elderly to seek medical help.

As mentioned earlier, the 4-2-1 family structure may limit the capacity of children to offer elderly care to their parents. However that may not be the only reason for a rising demand for social elderly care. The future elderly middle class—who has contributed to and enjoyed the fruit of China’s economic reform—may have a strong need for quality social healthcare services. For example, In addition, in order to meet rising demand, growth in the long term care facilities sector (including nursing homes and day care centres) is expected. Other healthcare services, including mental health support to the elderly, may also be an increasing need.

As China’s healthcare needs grow and the relative proportion of contributing labour force declines, public funding will no longer be sufficient to provide the care required. Private funding, including funding from families themselves as well as investment from both within China and from abroad, will increasingly be needed to close the gap and supplement public funding if China’s healthcare system is to avoid a crisis. 

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more at http://bit.ly/1FUw8Ng

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Video: Immuno-oncology therapies

Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high...

Event: EULAR Annual European Congress of Rheumatology 2016

We are delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Representing Research Partnership is Business Development Manager, Fara Mboge. He will be on hand to...

Forever Angels achievements and development plan for 2016

Research Partnership is proud to support Forever Angels in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania

The Opportunity for Women’s Health in Emerging Markets

Published in eyeforpharma April 2016 by Rachel Howard

Video: Storytelling in healthcare market research

Within the pharmaceutical industry, there is an increasing need for market research teams to share the insights with their key internal stakeholders, from marketing and brand managers to sales reps...

Promotions and new appointments across our global offices

Research Partnership is delighted to announce promotions and new starters in the UK and further appointments in the US and Singapore offices

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...

Webcast: Understanding the Chronic Disease Patient Journey in Emerging Markets

In emerging markets where primary care systems do not exist, the patient is the only constant in the journey

Living with Crohn’s Report

Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?

Infographic: Research Partnership

Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.